Inhibiting HMGB1 or NET formation may mitigate pulmonary inflammation in acute respiratory distress syndrome [101] and help treat inflammatory diseases such as diabetic wounds and COVID-19 [103,104]. Here, HMGB1 is linked to acute respiratory distress syndrome.